Based on the Novo Nordisk A/S stock forecast from 0 analysts, the average analyst target price for Novo Nordisk A/S is not available over the next 12 months. Novo Nordisk A/S’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Novo Nordisk A/S is Slightly Bullish , which is based on 4 positive signals and 3 negative signals. At the last closing, Novo Nordisk A/S’s stock price was EUR 121.86. Novo Nordisk A/S’s stock price has changed by +4.19% over the past week, -1.73% over the past month and 0% over the last year.
No recent analyst target price found for Novo Nordisk A/S
No recent average analyst rating found for Novo Nordisk A/S
Company Overview Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Read Less
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segmen...Read More
Frequently Asked Questions About Novo Nordisk A/S (NOV:F) Stock
Stock Target Advisor's fundamental analysis for Novo Nordisk A/S's stock is Slightly Bullish .
NOV:F stock's dividend yield is 1.13%.
Our analysis grades NOV:F stock's dividend yield at F. This means that NOV:F stock's dividend yield is above 30% of the stocks in the Biotechnology sector in the F exchange.
Based on this NOV:F may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on NOV:F's stock to indicate what its average analyst target is.
NOV:F stock's Price/Earning ratio is 43.48.
Our analysis grades NOV:F stock's Price / Earning ratio at F. This means that NOV:F stock's Price/Earning ratio is above 69% of the stocks in the Biotechnology sector in the F exchange.
Based on this NOV:F may be a overvalued for its sector.
The last closing price of NOV:F's stock was EUR 121.86.
The most recent market capitalization for NOV:F is EUR 526.04B.
Unfortunately we do not have enough analyst data on NOV:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Novo Nordisk A/S's stock.
As per our most recent records Novo Nordisk A/S has 69,260 Employees.
Novo Nordisk A/S's registered address is Novo Alle 1, Bagsvaerd, Denmark, 2880.
You can get more information about it from Novo Nordisk A/S's website at https://www.novonordisk.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Novo Nordisk A/S (NOV:F) Stock
Stock Target Advisor's fundamental analysis for Novo Nordisk A/S's stock is Slightly Bullish .
NOV:F stock's dividend yield is 1.13%.
Our analysis grades NOV:F stock's dividend yield at F. This means that NOV:F stock's dividend yield is above 30% of the stocks in the Biotechnology sector in the F exchange.
Based on this NOV:F may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on NOV:F's stock to indicate what its average analyst target is.
NOV:F stock's Price/Earning ratio is 43.48.
Our analysis grades NOV:F stock's Price / Earning ratio at F. This means that NOV:F stock's Price/Earning ratio is above 69% of the stocks in the Biotechnology sector in the F exchange.
Based on this NOV:F may be a overvalued for its sector.
The last closing price of NOV:F's stock was EUR 121.86.
The most recent market capitalization for NOV:F is EUR 526.04B.
Unfortunately we do not have enough analyst data on NOV:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Novo Nordisk A/S's stock.
As per our most recent records Novo Nordisk A/S has 69,260 Employees.
Novo Nordisk A/S's registered address is Novo Alle 1, Bagsvaerd, Denmark, 2880.
You can get more information about it from Novo Nordisk A/S's website at https://www.novonordisk.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NOV:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
